Pulse Biosciences, Inc (NASDAQ:PLSE) Director Maky Zanganeh bought 29,775 shares of the firm’s stock in a transaction dated Monday, September 18th. The stock was purchased at an average price of $13.36 per share, with a total value of $397,794.00. Following the transaction, the director now owns 315,725 shares in the company, valued at approximately $4,218,086. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Maky Zanganeh also recently made the following trade(s):
- On Wednesday, August 2nd, Maky Zanganeh bought 8,290 shares of Pulse Biosciences stock. The stock was purchased at an average price of $25.15 per share, with a total value of $208,493.50.
- On Thursday, August 3rd, Maky Zanganeh bought 28,790 shares of Pulse Biosciences stock. The stock was purchased at an average price of $23.96 per share, with a total value of $689,808.40.
Pulse Biosciences, Inc (NASDAQ:PLSE) opened at 15.00 on Wednesday. The firm’s market cap is $215.01 million. Pulse Biosciences, Inc has a 12 month low of $5.20 and a 12 month high of $39.50. The stock has a 50 day moving average price of $20.35 and a 200 day moving average price of $25.32.
Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, July 27th. The company reported ($0.43) earnings per share (EPS) for the quarter.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://sportsperspectives.com/2017/09/20/maky-zanganeh-buys-29775-shares-of-pulse-biosciences-inc-plse-stock.html.
A number of institutional investors and hedge funds have recently modified their holdings of PLSE. Schwab Charles Investment Management Inc. bought a new position in Pulse Biosciences during the second quarter valued at about $529,000. Rhumbline Advisers bought a new position in Pulse Biosciences during the second quarter valued at about $325,000. Bank of New York Mellon Corp bought a new position in Pulse Biosciences during the second quarter valued at about $897,000. Wells Fargo & Company MN increased its stake in Pulse Biosciences by 21,473.2% during the second quarter. Wells Fargo & Company MN now owns 53,933 shares of the company’s stock valued at $1,862,000 after acquiring an additional 53,683 shares during the period. Finally, Teachers Advisors LLC bought a new position in Pulse Biosciences during the second quarter valued at about $566,000. Hedge funds and other institutional investors own 9.56% of the company’s stock.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.